Advertisement
Pharmaceutical Companies
Subscribe to Pharmaceutical Companies

The Lead

Mylan Files Patent Challenge Relating to BREVIBLOC(R)

November 25, 2014 11:07 am | News | Comments

Mylan has confirmed that it and several subsidiaries have been sued by several Baxter subsidiaries in connection with the filing of an Abbreviated New Drug Application (ANDA) with the FDA for Esmolol HCl in Sodium Chloride Injection.    

FDA Approves Valeant’s ONEXTON Acne Gel

November 25, 2014 8:13 am | News | Comments

Valeant Pharmaceuticals has received approval from the FDA for ONEXTON Gel (clindamycin...

FDA Grants Priority Review to Two Bayer Respiratory Meds

November 25, 2014 7:51 am | by The Associated Press | News | Comments

Two medicines Bayer HealthCare Pharmaceuticals Inc. is testing for respiratory disorders will...

BMS and Five Prime Therapeutics to Evaluate Investigational Immunotherapies Opdivo and FPA008 in Six Tumor Types

November 24, 2014 4:09 pm | News | Comments

Bristol-Myers Squibb Company and Five Prime Therapeutics have entered into an exclusive clinical...

View Sample

FREE Email Newsletter

Amgen Ends Studies of Gastric Cancer Drug

November 24, 2014 2:45 pm | News | Comments

Amgen is ending late-stage trials of its gastric cancer treatment rilotumumab because patients who took the drug were more likely to die. Amgen said more patients died after treatment with rilotumumab and chemotherapy than with chemotherapy alone.

AstraZeneca to Expand Frederick, MA Biologics Manufacturing Center

November 24, 2014 8:46 am | News | Comments

AstraZeneca has announced plans to expand its biologics manufacturing center in Frederick, Md. The more than $200M project will increase production capacity at the facility to support AstraZeneca’s maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline.

Merck and NewLink Genetics to Collaborate on Investigational Ebola Vaccine

November 24, 2014 8:26 am | News | Comments

Merck and NewLink Genetics Corporation have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.       

Advertisement

Family Gets $6.75M in Botox Treatment Case

November 21, 2014 8:04 am | by DAVE GRAM, Associated Press | News | Comments

A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.        

Shire to Relocate Over 500 Jobs to Massachusetts

November 19, 2014 2:04 pm | News | Comments

Shire has announced plans to relocate over 500 positions to Massachusetts from its Chesterbrook, Pennsylvania site and establish Lexington, Massachusetts as the company's U.S. operational headquarters. The transition is a continuation of the company's 'One Shire' efficiency program and will streamline business globally through two principal locations - Massachusetts and Switzerland.

Knight Sells Priority Review Voucher to Gilead

November 19, 2014 8:15 am | News | Comments

Knight Therapeutics today announced the sale of its Neglected Tropical Disease Priority Review Voucher ("PRV"). Knight will receive US$125 million in cash from Gilead Sciences, Inc. in exchange for the PRV.        

Study Lifts Cloud Over Heart Drugs Zetia, Vytorin

November 18, 2014 8:31 am | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.

Clovis Oncology and GSK to Collaborate on Oncology Clinical Trial

November 18, 2014 8:12 am | News | Comments

Clovis Oncology has entered into a clinical trial collaboration with GlaxoSmithKline to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC).      

Advertisement

Actavis to Spend $66B on Allergan

November 17, 2014 10:24 am | by TOM MURPHY, AP Business Writer | News | Comments

Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally stop a months-long takeover push from Valeant Pharmaceuticals for the Botox maker.             

Zoetis to Purchase Assets of Abbott Animal Health

November 17, 2014 8:35 am | News | Comments

Zoetis today announced an agreement to purchase animal health assets of Abbott for a purchase price of $255 million. Abbott Animal Health is a companion animal health business focused on the veterinary surgical suite.      

BMS to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland

November 17, 2014 8:31 am | News | Comments

Bristol-Myers Squibb Company has announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company’s growing biologics portfolio.

Lemtrada Approved for Multiple Sclerosis

November 17, 2014 8:18 am | News | Comments

The U.S. Food and Drug Administration has approved Lemtrada, a treatment for relapsing multiple sclerosis made by the drugmaker Genzyme. The drug has already been approved by the European Medicines Agency for use in the European Union and in Canada and Australia.

Merck and Pfizer to Develop Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

November 17, 2014 8:15 am | News | Comments

Merck announced today that it has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

Advertisement

Allergan Soars on Deal Reports

November 17, 2014 8:11 am | by The Associated Press | News | Comments

Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the maker of Botox, which is embroiled in a takeover battle with Valeant Pharmaceuticals.

FDA Approves Janssen’s Schizoaffective Disorder Treatment

November 13, 2014 1:53 pm | News | Comments

Janssen Pharmaceuticals has announced that the FDA approved the supplemental New Drug Applications (sNDAs) for the once-monthly atypical long-acting antipsychotic INVEGA SUSTENNA (paliperidone palmitate) to treat schizoaffective disorder as either monotherapy or adjunctive therapy.

AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

November 13, 2014 8:23 am | News | Comments

Isis Pharmaceuticals and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively. The agreement builds on an existing collaboration between AstraZeneca and Isis Pharmaceuticals.

AstraZeneca Initiates Development Program for BRILINTA Reversal Agent

November 13, 2014 8:06 am | News | Comments

AstraZeneca has begun a pre-clinical development program to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations such as urgent surgery, or in the event of major bleeding.

Gene Study Boosts Interest in Heart Drug Zetia

November 12, 2014 5:09 pm | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

Scientists have discovered some rare gene mutations that give people naturally lower cholesterol levels and cut their risk of heart disease in half. The news is of great interest because a drug that mimics these mutations has long been sold without evidence that it cuts the chance of heart disease, even though it lowers cholesterol.

Missouri Panel Formed to Investigate Attorney General Koster’s Pharmaceutical Ties

November 12, 2014 3:03 pm | by SUMMER BALLENTINE, Associated Press | News | Comments

Missouri House Speaker Tim Jones on Wednesday created a committee of lawmakers to review allegations that Attorney General Chris Koster has been influenced by lobbyist perks and campaign contributions.         

Amgen and AstraZeneca Announce Brodalumab Phase III Results

November 12, 2014 9:01 am | News | Comments

AstraZeneca and Amgen today announced that AMAGINE-3TM, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12

Allergan Amends Company’s Bylaws Prior to Stockholder's Meeting

November 12, 2014 8:12 am | News | Comments

Allergan today announced that its Board of Directors has approved amendments to the company’s bylaws that streamline the process associated with calling a special meeting of stockholders. The Board determined to amend the bylaws after meetings with many of the Company’s major stockholders and other governance organizations to solicit their input and perspectives.

GE Healthcare and Takeda to Develop Therapeutic Drugs to Target Liver Diseases

November 11, 2014 8:13 am | News | Comments

GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases.   

Dendreon Files for Bankruptcy Protection

November 10, 2014 8:29 am | by TOM MURPHY, AP Business Writer | News | Comments

Dendreon is seeking Chapter 11 bankruptcy protection and has reached a financial restructuring agreement with investors holding more than $520 million in debt. The Seattle company listed more than $664 million in total debts and $364.6 million in assets in a U.S. Bankruptcy Court filing on Monday.

AstraZeneca to Divest Myalept to Aegerion

November 6, 2014 10:44 am | News | Comments

AstraZeneca has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™ (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy.

Isis Pharmaceuticals Earns $7.5M Milestone Payment from AstraZeneca

November 6, 2014 8:52 am | News | Comments

Isis Pharmaceuticals has earned a $7.5 million milestone payment, the first of two milestone payments totaling $15 million, from AstraZeneca for the advancement of ISIS-STAT3Rx, also referred to as AZD9150, in patients with advanced cancers.  

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading